Citations (103)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Yan Wu, Shan Liu, Dongmei Wang & Xinjie Yao. (2023) Acute Myeloid Leukemia Secondary to Chronic Lymphocytic Leukemia After Prolonged Chlorambucil Therapy: A Case Report. Pharmacogenomics and Personalized Medicine 16, pages 401-405.
Read now
Read now
Andrés Gómez-De León, Roberta Demichelis-Gómez, Alfredo Pinedo-Rodríguez, Daniel Enriquez-Vera, Juan Antonio Flores-Jiménez, Adrián Alejandro Ceballos-López, Margarita Rodríguez-Mejorada, Miguel Angel Herrera Riojas, Roberto Ovilla-Martínez, Pamela Báez-Islas, Xóchitl Cota-Rangel, Yvette Neme-Yunes, Sergio Inclán-Alarcón, Nelson J. López-Flores, Perla R. Colunga-Pedraza, Anna C. Rodríguez-Zúñiga & David Gómez-Almaguer. (2022) Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America. Hematology 27:1, pages 249-257.
Read now
Read now
Omar Raslan & Alejandro Garcia-Horton. (2022) Azacitidine and its role in the upfront treatment of acute myeloid leukemia. Expert Opinion on Pharmacotherapy 23:8, pages 873-884.
Read now
Read now
Davis F. Phillips & Joshua F. Zeidner. (2021) Emerging therapies for AML with myelodysplasia-related changes: slowly but surely moving the needle. Expert Opinion on Emerging Drugs 26:3, pages 245-257.
Read now
Read now
Sonal Agarwal, Andrew Kowalski, Molly Schiffer, Jennifer Zhao, Jan Philipp Bewersdorf & Amer M. Zeidan. (2021) Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?. Expert Review of Hematology 14:2, pages 199-210.
Read now
Read now
Alexandre Bazinet & Sarit Assouline. (2021) A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’. Expert Review of Hematology 14:2, pages 185-197.
Read now
Read now
Dong Won Baek, Juhyung Kim, Hee Jeong Cho, Joon Ho Moon & Sang Kyun Sohn. (2020) Hypomethylating agent-based post-transplant strategies to maximize the outcome of high-risk acute myeloid leukemia after allogeneic stem cell transplantation. Expert Review of Hematology 13:9, pages 959-969.
Read now
Read now
Toshihisa Satta & Steven Grant. (2020) Enhancing venetoclax activity in hematological malignancies. Expert Opinion on Investigational Drugs 29:7, pages 697-708.
Read now
Read now
Curtis Lachowiez, Courtney D. DiNardo & Marina Konopleva. (2020) Venetoclax in acute myeloid leukemia – current and future directions . Leukemia & Lymphoma 61:6, pages 1313-1322.
Read now
Read now
Ulrich Germing, Thomas Schroeder, Jennifer Kaivers, Andrea Kündgen, Guido Kobbe & Norbert Gattermann. (2019) Novel therapies in low- and high-risk myelodysplastic syndrome. Expert Review of Hematology 12:10, pages 893-908.
Read now
Read now
Shannon R. McCurdy & Mark J. Levis. (2018) Emerging molecular predictive and prognostic factors in acute myeloid leukemia. Leukemia & Lymphoma 59:9, pages 2021-2039.
Read now
Read now
Meera Yogarajah & Richard M. Stone. (2018) A concise review of BCL-2 inhibition in acute myeloid leukemia. Expert Review of Hematology 11:2, pages 145-154.
Read now
Read now
Andrew Wei. (2015) ABT-199 partners with azacitidine to contest myeloid malignancies. Leukemia & Lymphoma 56:1, pages 8-9.
Read now
Read now
Articles from other publishers (90)
Heather J. Male & Tara L. Lin. (2023) The approach of HMA plus VEN with or without BMT for all patients with AML. Hematology 2023:1, pages 186-191.
Crossref
Crossref
Xinhui Zheng, Hongye Gao, Ni Lu, Mingyang Wang, Haixiao Zhang, Yawei Zheng, Biao Shen, Yigeng Cao, Xin Chen, Weihua Zhai, Jialin Wei, Donglin Yang, Rongli Zhang, Aiming Pang, Sizhou Feng, Erlie Jiang & Mingzhe Han. (2023) Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms. Annals of Hematology 102:12, pages 3603-3611.
Crossref
Crossref
Xiaobo Wang, Lihua Yuan, Bo Lu, Dongjun Lin & Xiaojun Xu. (2023) Glutathione promotes the synergistic effects of venetoclax and azacytidine against myelodysplastic syndrome‑refractory anemia by regulating the cell cycle. Experimental and Therapeutic Medicine 26:6.
Crossref
Crossref
Alexandra Rezazadeh, Michael Deininger & Ehab Atallah. (2023) Proposals for Clinical Trials in Chronic Myelomonocytic Leukemia. Current Treatment Options in Oncology 24:8, pages 1036-1051.
Crossref
Crossref
Thomas Systchenko, Jean‐Claude Chomel, Pilar Gallego‐Hernanz, Niels Moya, Déborah Desmier, Natacha Maillard, Arthur Bobin, Mathilde Vonfeld, Hélène Gardeney, Emilie Cayssials E & José Torregrosa. (2023) Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms. British Journal of Haematology 202:2, pages 284-288.
Crossref
Crossref
Jennifer A. Marks, Xin Wang, Elena M. Fenu, Adam Bagg & Catherine Lai. (2023) TP53 in AML and MDS: The new (old) kid on the block. Blood Reviews 60, pages 101055.
Crossref
Crossref
Lejiao Jia, Huatian Yang, Dandan Zheng, Jingjing Ye, Qian Zhou, Genjv Li, Ying Zhou, Xinyu Yang, Jinting Liu, Feng Ye, Yuliang Song, Daoxin Ma & Chunyan Ji. (2023) Smart and Generalizable Cytarabine Derivative-Triggered Nanoparticles for Synergistic Therapy of Relapsed/Refractory Acute Myeloid Leukemia. ACS Applied Materials & Interfaces 15:23, pages 27624-27637.
Crossref
Crossref
Matteo Piccini, Francesco Mannelli & Giacomo Coltro. (2023) The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions. Bioengineering 10:5, pages 591.
Crossref
Crossref
Yasmin Abaza & Anand Ashwin Patel. (2023) Novel Therapies in Myelodysplastic Syndrome. The Cancer Journal 29:3, pages 188-194.
Crossref
Crossref
Hua Jin, Yu Zhang, Sijian Yu, Xin Du, Na Xu, Ruoyang Shao, Dongjun Lin, Yanqiu Chen, Jie Xiao, Zhiqiang Sun, Lan Deng, Xinquan Liang, Hongyu Zhang, Ziwen Guo, Min Dai, Pengcheng Shi, Fen Huang, Zhiping Fan, Zhao Yin, Li Xuan, Ren Lin, Xuejie Jiang, Guopan Yu & Qifa Liu. (2023) Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial. Journal of Hematology & Oncology 16:1.
Crossref
Crossref
Gaku Oshikawa & Koji Sasaki. (2023) Optimizing Treatment Options for Newly Diagnosed Acute Myeloid Leukemia in Older Patients with Comorbidities. Cancers 15:8, pages 2399.
Crossref
Crossref
Rong-Hua Hu, Li Su, Xiao-Xi Lan, Xiao-Li Chang, Wu-Han Hui, Yi-Xian Guo, Hong Zhao, Yue Zhang & Wan-Ling Sun. (2022) A retrospective assessment of real-world experience with venetoclax and azacitidine therapy in elderly acute myeloid leukemia. Anti-Cancer Drugs 34:3, pages 344-350.
Crossref
Crossref
Zhihong Zeng, Abhishek Maiti, Shelley Herbrich, Tianyu Cai, Antonio Cavazos, Taylor Manzella, Helen Ma, Kala Hayes, Jairo Matthews, Courtney D. DiNardo, Naval G. Daver & Marina Y. Konopleva. (2022) Triple combination targeting methyltransferase, BCL‐2, and PD‐1 facilitates antileukemia responses in acute myeloid leukemia. Cancer 129:4, pages 531-540.
Crossref
Crossref
Robert Briski, Guillermo Garcia-Manero, Hagop Kantarjian & Farhad Ravandi. (2023) The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia. Therapeutic Advances in Hematology 14.
Crossref
Crossref
Daehun Kwag, Byung-Sik Cho, Su-Yeon Bang, Jong Hyuk Lee, Gi-June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Jong Wook Lee & Hee-Je Kim. (2022) Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis. Blood Cancer Journal 12:12.
Crossref
Crossref
E. V. Usikova, K. D. Kaplanov, V. I. Vorob'ev, T. I. Lobanova, M. A. Ul'yanova, D. G. Kisilichina, Yu. N. Kobzev, D. I. Shikhbabaeva, O. Yu. Vinogradova & V. V. Ptushkin. (2022) Efficacy of the combination of venetoclax and hypomethylating agents in the treatment of patients with primary, relapsed and/or refractory acute myeloid leukemia. Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH) 12:6, pages 64-77.
Crossref
Crossref
Brian J. Ball, Paul B. Koller & Vinod Pullarkat. (2022) Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia. Current Opinion in Oncology 34:5, pages 531-539.
Crossref
Crossref
Hiroto Ishii & Shingo Yano. (2022) New Therapeutic Strategies for Adult Acute Myeloid Leukemia. Cancers 14:11, pages 2806.
Crossref
Crossref
Deanna Brackman, Doerthe Eckert, Rajeev Menon, Ahmed Hamed Salem, Jalaja Potluri, B. Douglas Smith, Andrew H. Wei, John Hayslip, Dale Miles, Sven Mensing, Sathej Gopalakrishnan & Jiuhong Zha. (2022) Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy. Hematological Oncology 40:2, pages 269-279.
Crossref
Crossref
Kristína Šimoničová, Ľuboš Janotka, Helena Kavcová, Zdena Sulová, Albert Breier & Lucia Messingerova. (2022) Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia. Drug Resistance Updates 61, pages 100805.
Crossref
Crossref
Yao Qin, Pu Kuang & Ting Liu. (2022) Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis. Clinical and Experimental Medicine 23:2, pages 219-227.
Crossref
Crossref
Kazuhito Yamamoto, Atsushi Shinagawa, Courtney D DiNardo, Keith W Pratz, Kenichi Ishizawa, Toshihiro Miyamoto, Norio Komatsu, Yasuhiro Nakashima, Chikashi Yoshida, Noriko Fukuhara, Kensuke Usuki, Takahiro Yamauchi, Noboru Asada, Norio Asou, Ilseung Choi, Yasushi Miyazaki, Hideyuki Honda, Sumiko Okubo, Misaki Kurokawa, Ying Zhou, Jiuhong Zha, Jalaja Potluri & Itaru Matsumura. (2022) Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Japanese Journal of Clinical Oncology 52:1, pages 29-38.
Crossref
Crossref
M.A. Granatkin, Evgenii Aleksandrovich Nikitin, E.S. Mikhailov, V.A. Doronin, S.V. Minenko, M.M. Okuneva, N.V. Degtyareva, M.E. Pochtar, S.A. Lugovskaya, Yu.N. Kobzev, O.Yu. Vinogradova & V.V. Ptushkin. (2022) Azacitidine/Venetoclax Combination as First-Line Therapy in Elderly Patients with Acute Myeloid Leukemias: A First Step. Clinical oncohematology 15:3, pages 282-288.
Crossref
Crossref
Qiuyun Fang, Xiaoyuan Gong, Yan Li, Benfa Gong, Yuntao Liu, Kaiqi Liu, Guangji Zhang, Shuning Wei, Dong Lin, Bingcheng Liu, Ying Wang, Hui Wei, Yingchang Mi & Jianxiang Wang. (2022) The impact of venetoclax based regimens in the preemptive of measurable residual disease in acute myeloid leukemia. Blood Science 4:1, pages 44-46.
Crossref
Crossref
Sarah T. Diepstraten, Mary Ann Anderson, Peter E. Czabotar, Guillaume Lessene, Andreas Strasser & Gemma L. Kelly. (2021) The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nature Reviews Cancer 22:1, pages 45-64.
Crossref
Crossref
Serena Brancati, Lucia Gozzo, Giovanni Luca Romano, Calogero Vetro, Ilaria Dulcamare, Cinzia Maugeri, Marina Parisi, Laura Longo, Daniela Cristina Vitale, Francesco Di Raimondo & Filippo Drago. (2021) Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?. Cancers 14:1, pages 22.
Crossref
Crossref
Philipp Makowka, Verena Stolp, Karoline Stoschek & Hubert Serve. (2021) Molecular determinants of therapy response of venetoclax-based combinations in acute myeloid leukemia. Biological Chemistry 402:12, pages 1547-1564.
Crossref
Crossref
Paul A. Townsend, Maria V. Kozhevnikova, Olivier N. F. Cexus, Andrey A. ZamyatninJrJr & Surinder M. Soond. (2021) BH3-mimetics: recent developments in cancer therapy. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Crossref
Irene Urbino, Carolina Secreto, Matteo Olivi, Vincenzo Apolito, Stefano D’Ardia, Chiara Frairia, Valentina Giai, Semra Aydin, Roberto Freilone, Chiara Dellacasa, Luisa Giaccone, Dario Ferrero, Ernesta Audisio, Alessandro Busca & Marco Cerrano. (2021) Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021. Cancers 13:20, pages 5075.
Crossref
Crossref
Jasmin Straube, Steven W. Lane & Therese Vu. (2021) Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes. BioEssays 43:10.
Crossref
Crossref
Thomas Cluzeau, Michael Loschi, Pierre Fenaux, Rami Komrokji & David A. Sallman. (2021) Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. International Journal of Molecular Sciences 22:18, pages 10105.
Crossref
Crossref
Rory M. Shallis & Amer M. Zeidan. (2021) Management of the Older Patient with Myelodysplastic Syndrome. Drugs & Aging 38:9, pages 751-767.
Crossref
Crossref
Xiaoli Ju, Zhilong Yang, Heng Zhang & Qiang Wang. (2021) Role of pyroptosis in cancer cells and clinical applications. Biochimie 185, pages 78-86.
Crossref
Crossref
Moo-Kon Song, Byeong-Bae Park & Ji-Eun Uhm. (2021) Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia. International Journal of Molecular Sciences 22:11, pages 5789.
Crossref
Crossref
Shuichi Taniguchi, Takahiro Yamauchi, Ilseung Choi, Noriko Fukuhara, Jalaja Potluri, Ahmed Hamed Salem, Wan-Jen Hong, Hideyuki Honda, Yasuko Nishimura, Sumiko Okubo & Kensuke Usuki. (2021) Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings. Japanese Journal of Clinical Oncology 51:6, pages 857-864.
Crossref
Crossref
John C. Molina, Julie M. Asare, Laura Tuschong, Robert R. West, Katherine R. Calvo, Rebecca Persky, Alison M. Boyce, Dima A. Hammoud, Steven M. Holland, Dennis Hickstein & Nirali N. Shah. (2020) Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia. Pediatric Blood & Cancer 68:3.
Crossref
Crossref
Narissa Parry, Helen Wheadon & Mhairi Copland. (2021) The application of BH3 mimetics in myeloid leukemias. Cell Death & Disease 12:2.
Crossref
Crossref
Daniel A. Pollyea, Keith Pratz, Anthony Letai, Brian A. Jonas, Andrew H. Wei, Vinod Pullarkat, Marina Konopleva, Michael J. Thirman, Martha Arellano, Pamela S. Becker, Brenda Chyla, Wan‐Jen Hong, Qi Jiang, Jalaja Potluri & Courtney D. DiNardo. (2020) Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study. American Journal of Hematology 96:2, pages 208-217.
Crossref
Crossref
Shinichiro Takahashi. (2021) Current Understandings of Myeloid Differentiation Inducers in Leukemia Therapy. Acta Haematologica 144:4, pages 380-388.
Crossref
Crossref
Yufan Wang & Liang Wang. (2020) Application and research progress of BCL2 inhibitors in elderly patients with hematologic malignancies. Aging Pathobiology and Therapeutics 2:4, pages 180-186.
Crossref
Crossref
Cihangir Duy, Wendy Béguelin & Ari Melnick. (2020) Epigenetic Mechanisms in Leukemias and Lymphomas. Cold Spring Harbor Perspectives in Medicine 10:12, pages a034959.
Crossref
Crossref
Yunxiong Wei, Yaqing Cao, Rui Sun, Lin Cheng, Xia Xiong, Xin Jin, Xiaoyuan He, Wenyi Lu & Mingfeng Zhao. (2020) Targeting Bcl-2 Proteins in Acute Myeloid Leukemia. Frontiers in Oncology 10.
Crossref
Crossref
Bachar Samra, Marina Konopleva, Alessandro Isidori, Naval Daver & Courtney DiNardo. (2020) Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions. Frontiers in Oncology 10.
Crossref
Crossref
Amanda C. Winters, Kelly W. Maloney, Amy L. Treece, Lia Gore & Anna K. Franklin. (2020) Single‐center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. Pediatric Blood & Cancer 67:10.
Crossref
Crossref
Courtney D. DiNardoBrian A. JonasVinod PullarkatMichael J. ThirmanJacqueline S. GarciaAndrew H. WeiMarina KonoplevaHartmut DöhnerAnthony LetaiPierre FenauxElizabeth KollerViolaine HavelangeBrian LeberJordi EsteveJianxiang WangVlatko PejsaRoman HájekKimmo PorkkaÁrpád IllésDavid LavieRoberto M. LemoliKazuhito YamamotoSung-Soo YoonJun-Ho JangSu-Peng YehMehmet TurgutWan-Jen HongYing ZhouJalaja PotluriKeith W. Pratz. (2020) Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. New England Journal of Medicine 383:7, pages 617-629.
Crossref
Crossref
Benedito A. Carneiro & Wafik S. El-Deiry. (2020) Targeting apoptosis in cancer therapy. Nature Reviews Clinical Oncology 17:7, pages 395-417.
Crossref
Crossref
Michael A. Spinner, Alexey Aleshin, Marianne T. Santaguida, Steven A. Schaffert, James L. Zehnder, A. Scott Patterson, Christos Gekas, Diane Heiser & Peter L. Greenberg. (2020) Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms. Blood Advances 4:12, pages 2768-2778.
Crossref
Crossref
Andrew H. WeiPau MontesinosVladimir IvanovCourtney D. DiNardo, Jan NovakKamel LaribiInho KimDon A. StevensWalter FiedlerMaria PagoniOlga SamoilovaYu Hu, Achilles Anagnostopoulos, Julie BergeronJing-Zhou HouVidhya MurthyTakahiro YamauchiAndrew McDonaldBrenda Chyla, Sathej Gopalakrishnan, Qi Jiang, Wellington Mendes, John Hayslip & Panayiotis Panayiotidis. (2020) Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135:24, pages 2137-2145.
Crossref
Crossref
Alessandro Fiorentini, Debora Capelli, Francesco Saraceni, Diego Menotti, Antonella Poloni & Attilio Olivieri. (2020) The Time Has Come for Targeted Therapies for AML: Lights and Shadows. Oncology and Therapy 8:1, pages 13-32.
Crossref
Crossref
Jun H. Choi, James M. Bogenberger & Raoul Tibes. (2020) Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond. Targeted Oncology 15:2, pages 147-162.
Crossref
Crossref
Rory M. Shallis, Prajwal C. Boddu, Jan Philipp Bewersdorf & Amer M. Zeidan. (2020) The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia. Blood Reviews 40, pages 100639.
Crossref
Crossref
Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea & Andre C. Schuh. (2020) Response Kinetics and Clinical Benefits of Nonintensive AML Therapies in the Absence of Morphologic Response. Clinical Lymphoma Myeloma and Leukemia 20:2, pages e66-e75.
Crossref
Crossref
Hongxia Wang, Junjun Bai, Zhixin Pei, Bei Zhang, Junjie Wang, Xingli Lian & Qinglin Song. (2020) Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia. Medicine 99:47, pages e23265.
Crossref
Crossref
Daniel A. Pollyea, Maria Amaya, Paolo Strati & Marina Y. Konopleva. (2019) Venetoclax for AML: changing the treatment paradigm. Blood Advances 3:24, pages 4326-4335.
Crossref
Crossref
Raoul Tibes & James M. Bogenberger. (2019) Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia. Frontiers in Oncology 9.
Crossref
Crossref
Ing S. Tiong & Andrew H. Wei. (2019) New drugs creating new challenges in acute myeloid leukemia. Genes, Chromosomes and Cancer 58:12, pages 903-914.
Crossref
Crossref
Suresh Agarwal, Sathej Gopalakrishnan, Sven Mensing, Jalaja Potluri, John Hayslip, Whitney Kirschbrown, Anna Friedel, Rajeev Menon & Ahmed Hamed Salem. (2019) Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure‐response analysis. Hematological Oncology 37:4, pages 464-473.
Crossref
Crossref
Matthieu Duchmann & Raphael Itzykson. (2019) Clinical update on hypomethylating agents. International Journal of Hematology 110:2, pages 161-169.
Crossref
Crossref
Xufeng Chen, Christina Glytsou, Hua Zhou, Sonali Narang, Denis E. Reyna, Andrea Lopez, Theodore Sakellaropoulos, Yixiao Gong, Andreas Kloetgen, Yoon Sing Yap, Eric Wang, Evripidis Gavathiotis, Aristotelis Tsirigos, Raoul Tibes & Iannis Aifantis. (2019) Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment. Cancer Discovery 9:7, pages 890-909.
Crossref
Crossref
Musa Yilmaz & Naval Daver. (2019) From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia. Drugs 79:11, pages 1177-1186.
Crossref
Crossref
Veronica A. Guerra, Courtney DiNardo & Marina Konopleva. (2019) Venetoclax-based therapies for acute myeloid leukemia. Best Practice & Research Clinical Haematology 32:2, pages 145-153.
Crossref
Crossref
Andrew H. Wei, Stephen A. StricklandJrJr, Jing-Zhou Hou, Walter Fiedler, Tara L. Lin, Roland B. Walter, Anoop Enjeti, Ing Soo Tiong, Michael Savona, Sangmin Lee, Brenda Chyla, Relja Popovic, Ahmed Hamed Salem, Suresh Agarwal, Tu Xu, Kaffa M. Fakouhi, Rod Humerickhouse, Wan-Jen Hong, John Hayslip & Gail J. Roboz. (2019) Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology 37:15, pages 1277-1284.
Crossref
Crossref
Elisabete do Vale Campos & Ricardo Pinto. (2019) Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia. Hematology, Transfusion and Cell Therapy 41:2, pages 169-177.
Crossref
Crossref
Amanda McBride, Sarah Houtmann, Lindsay Wilde, Carlos Vigil, Christine M. Eischen, Margaret Kasner & Neil Palmisiano. (2019) The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome. Frontiers in Oncology 9.
Crossref
Crossref
Daniel A. Pollyea & Craig T. Jordan. (2019) Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?. Current Opinion in Hematology 26:2, pages 71-76.
Crossref
Crossref
Edna Cheung, Anthony J. Perissinotti, Dale L. Bixby, Patrick W. Burke, Kristen M. Pettit, Lydia L. Benitez, Julia Brown, Gianni B. Scappaticci & Bernard L. Marini. (2019) The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. Annals of Hematology 98:3, pages 541-559.
Crossref
Crossref
Courtney D. DiNardoKeith PratzVinod PullarkatBrian A. JonasMartha ArellanoPamela S. BeckerOlga FrankfurtMarina KonoplevaAndrew H. WeiHagop M. KantarjianTu XuWan-Jen HongBrenda ChylaJalaja PotluriDaniel A. Pollyea & Anthony Letai. (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:1, pages 7-17.
Crossref
Crossref
Guillaume Richard-Carpentier & Courtney D. DiNardo. (2019) Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Therapeutic Advances in Hematology 10, pages 204062071988282.
Crossref
Crossref
Kanak Joshi, Lei Zhang, Peter Breslin S.J.Jiwang Zhang. 2019. Leukemia Stem Cells in Hematologic Malignancies. Leukemia Stem Cells in Hematologic Malignancies
95
128
.
Ahmet Can Timucin, Huveyda Basaga & Ozgur Kutuk. (2019) Selective targeting of antiapoptotic BCL-2 proteins in cancer. Medicinal Research Reviews 39:1, pages 146-175.
Crossref
Crossref
Haley E. Ramsey, Melissa A. Fischer, Taekyu Lee, Agnieszka E. Gorska, Maria Pia Arrate, Londa Fuller, Kelli L. Boyd, Stephen A. Strickland, John Sensintaffar, Leah J. Hogdal, Gregory D. Ayers, Edward T. Olejniczak, Stephen W. Fesik & Michael R. Savona. (2018) A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discovery 8:12, pages 1566-1581.
Crossref
Crossref
Daniel A. Pollyea, Brett M. Stevens, Courtney L. Jones, Amanda Winters, Shanshan Pei, Mohammad Minhajuddin, Angelo D’Alessandro, Rachel Culp-Hill, Kent A. Riemondy, Austin E. Gillen, Jay R. Hesselberth, Diana Abbott, Derek Schatz, Jonathan A. Gutman, Enkhtsetseg Purev, Clayton Smith & Craig T. Jordan. (2018) Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nature Medicine 24:12, pages 1859-1866.
Crossref
Crossref
Jacqueline L Olin, Carrie L Griffiths & Morgan B Smith. (2017) Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies. Journal of Oncology Pharmacy Practice 24:7, pages 517-524.
Crossref
Crossref
Simone Fulda. (2018) Therapeutic opportunities based on caspase modulation. Seminars in Cell & Developmental Biology 82, pages 150-157.
Crossref
Crossref
Rebecca Valentin, Stephanie Grabow & Matthew S. Davids. (2018) The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood 132:12, pages 1248-1264.
Crossref
Crossref
Marina Konopleva & Anthony Letai. (2018) BCL-2 inhibition in AML: an unexpected bonus?. Blood 132:10, pages 1007-1012.
Crossref
Crossref
Andrew E Place, Kelly Goldsmith, Jean-Pierre Bourquin, Mignon L Loh, Lia Gore, Daniel A Morgenstern, Yeshwant Sanzgiri, David Hoffman, Ying Zhou, Jeremy A Ross, Betty Prine, Mohamad Shebley, Megan McNamee, Thalia Farazi, Su Young Kim, Maria Verdugo, Leanne Lash-Fleming, C Michel Zwaan & Josef Vormoor. (2018) Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies. Future Oncology 14:21, pages 2115-2129.
Crossref
Crossref
Leena T. Rahmat, Anna Nguyen, Haifaa Abdulhaq, Sonam Prakash, Aaron C. Logan & Gabriel N. Mannis. (2018) Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant. Case Reports in Hematology 2018, pages 1-4.
Crossref
Crossref
Prashant Sharma & Daniel A Pollyea. (2018) Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition. Current Hematologic Malignancy Reports 13:4, pages 256-264.
Crossref
Crossref
Veronika Reidel, Johanna Kauschinger, Richard T. Hauch, Catharina Müller-Thomas, Niroshan Nadarajah, Rainer Burgkart, Burkhard Schmidt, Dirk Hempel, Anne Jacob, Julia Slotta-Huspenina, Ulrike Höckendorf, Christian Peschel, Wolfgang Kern, Torsten Haferlach, Katharina S. Götze, Stefanie Jilg & Philipp J. Jost. (2018) Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile. Oncotarget 9:25, pages 17270-17281.
Crossref
Crossref
Courtney D. DiNardo, Caitlin R. Rausch, Christopher Benton, Tapan Kadia, Nitin Jain, Naveen Pemmaraju, Naval Daver, Wendy Covert, Kayleigh R. Marx, Morgan Mace, Elias Jabbour, Jorge Cortes, Guillermo Garcia-Manero, Farhad Ravandi, Kapil N. Bhalla, Hagop Kantarjian & Marina Konopleva. (2018) Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. American Journal of Hematology 93:3, pages 401-407.
Crossref
Crossref
Courtney D DiNardo, Keith W Pratz, Anthony Letai, Brian A Jonas, Andrew H Wei, Michael Thirman, Martha Arellano, Mark G Frattini, Hagop Kantarjian, Relja Popovic, Brenda Chyla, Tu Xu, Martin Dunbar, Suresh K Agarwal, Rod Humerickhouse, Mack Mabry, Jalaja Potluri, Marina Konopleva & Daniel A Pollyea. (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. The Lancet Oncology 19:2, pages 216-228.
Crossref
Crossref
Qing Wang, Pu Wang, Hong Zhou, Yan Hu, Chengshen Xie, Fei Gao, Ningjie Ma, Haoli Hou, Hao Zhang & Lijia Li. (2017) 5‐Azacytidine specifically inhibits the NIH‐3T3 PCD process induced by TNF‐alpha and cycloheximide via affecting BCL‐XL. Journal of Cellular Biochemistry 119:2, pages 1501-1510.
Crossref
Crossref
James Bogenberger, Clifford Whatcott, Nanna Hansen, Devora Delman, Chang-Xin Shi, Wontak Kim, Hillary Haws, Katherine Soh, Ye Sol Lee, Peter Peterson, Adam Siddiqui-Jain, Steven Weitman, Keith Stewart, David Bearss, Ruben Mesa, Steven Warner & Raoul Tibes. (2017) Combined venetoclax and alvocidib in acute myeloid leukemia. Oncotarget 8:63, pages 107206-107222.
Crossref
Crossref
Joel D. Leverson, Deepak Sampath, Andrew J. Souers, Saul H. Rosenberg, Wayne J. Fairbrother, Martine Amiot, Marina Konopleva & Anthony Letai. (2017) Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax. Cancer Discovery 7:12, pages 1376-1393.
Crossref
Crossref
Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri, Brenda Chyla, Leah Hogdal, Todd Busman, Evelyn McKeegan, Ahmed Hamed Salem, Ming Zhu, Justin L. Ricker, William Blum, Courtney D. DiNardo, Tapan Kadia, Martin Dunbar, Rachel Kirby, Nancy Falotico, Joel Leverson, Rod Humerickhouse, Mack Mabry, Richard Stone, Hagop Kantarjian & Anthony Letai. (2016) Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discovery 6:10, pages 1106-1117.
Crossref
Crossref
Harinder Gill, Anskar Leung & Yok-Lam Kwong. (2016) Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy. International Journal of Molecular Sciences 17:4, pages 440.
Crossref
Crossref
Raoul Tibes, Aref Al-Kali, Gavin R Oliver, Devora H Delman, Nanna Hansen, Keerthi Bhagavatula, Jayaram Mohan, Fariborz Rakhshan, Thomas Wood, James M. Foran, Ruben A. Mesa & James M. Bogenberger. (2015) The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia. Journal of Hematology & Oncology 8:1.
Crossref
Crossref
Joel D. LeversonDarren C. PhillipsMichael J. MittenErwin R. BoghaertDolores DiazStephen K. TahirLisa D. BelmontPaul NimmerYu XiaoXiaoju Max MaKym N. LowesPeter KovarJun ChenSha JinMorey SmithJohn XueHaichao ZhangAnatol OleksijewTerrance J. MagocKedar S. VaidyaDaniel H. AlbertJacqueline M. TarrantNghi LaLe WangZhi-Fu TaoMichael D. WendtDeepak SampathSaul H. RosenbergChris TseDavid C. S. HuangWayne J. FairbrotherSteven W. ElmoreAndrew J. Souers. (2015) Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Science Translational Medicine 7:279.
Crossref
Crossref
Clare Sun & Adrian Wiestner. 2015. Non-Hodgkin Lymphoma. Non-Hodgkin Lymphoma
147
175
.